INCB018424 is an orally bioavailable JAK inhibitor with potential antineoplastic and immunomodulating activities. INCB018424, a characterized JAK1/JAK2 inhibitor (IC50 values for JAK1, JAK2 and JAK3 are 3, 5 and 332 nM, respectively), has reached clinical trials for oncology indications, rheumatoid arthritis, and psoriasis. This compound is worth noting due to its opposite potency profile in the inhibition of the JAK enzymes when compared to CP-690,550.

June 21, 2017

prudect name : INCB018424 is an orally bioavailable JAK inhibitor with potential antineoplastic and immunomodulating activities. INCB018424, a characterized JAK1/JAK2 inhibitor (IC50 values for JAK1, JAK2 and JAK3 are 3, 5 and 332 nM, respectively), has reached clinical trials for oncology indications, rheumatoid arthritis, and psoriasis. This compound is worth noting due to its opposite potency profile in the inhibition of the JAK enzymes when compared to CP-690,550.
INCB 018424 Ruxolitinib

Synonyms: RuxolitinibCAS NO: 941678-49-5 Molecular Formula: C₁₇H₁₈N₆Molecular Weight: 306.37Purity: 98% minSolubility: In DMSOStorage: −20°C

CHIR 99021 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18520392